WaveMan · Form 4
Schneider Eugene insider trades
> Search tickers & screens ⌘K
LIVE

Schneider Eugene insider trades

Schneider Eugene has filed 25 Form 4s with the SEC that we hold, all for Ionis Pharmaceuticals INC (IONS), as EVP, Chf Clinical Develop Ofcr. Across all of them we count 0 purchases worth $0 and 16 sales worth $8.0M reported on Form 4. In the last 12 months: 0 purchases ($0) and 4 sales ($3.7M). The largest single trade was a sale of 26,000 shares of Ionis Pharmaceuticals INC worth $2.1M, dated 2026-06-26. The first filing on our record is dated 2021-10-19 and the latest 2026-06-30.

Ionis Pharmaceuticals INC (IONS)

EVP, Chf Clinical Develop Ofcr · 25 filings · 16 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-01-18S, sale reported on Form 44,752$188.0K2023-01-19
2023-02-06S, sale reported on Form 41,413$57.5K2023-02-07
2023-12-26S, sale reported on Form 425,000$1.3M2023-12-28
2024-01-12S, sale reported on Form 48,000$428.0K2024-01-17
2024-01-17S, sale reported on Form 45,482$276.4K2024-01-18
2024-02-02S, sale reported on Form 42,071$102.7K2024-02-02
2024-02-02S, sale reported on Form 42,106$104.4K2024-09-04
2025-01-16S, sale reported on Form 46,523$213.9K2025-01-17
2025-01-31S, sale reported on Form 41,484$47.8K2025-02-03
2025-08-04S, sale reported on Form 49,549$408.7K2025-08-05
2025-09-03S, sale reported on Form 412,455$753.0K2025-09-04
2025-09-03S, sale reported on Form 47,203$442.4K2025-09-04
2026-01-16S, sale reported on Form 49,302$703.1K2026-01-20
2026-01-30S, sale reported on Form 46,179$515.6K2026-02-02
2026-03-19S, sale reported on Form 45,812$412.5K2026-03-23
2026-06-26S, sale reported on Form 426,000$2.1M2026-06-30
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1838539) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms